Skip to contentA
Arcutis Biotherapeutics, Inc.
A
ARQTArcutis Biotherapeutics, Inc. Q3 2025 · 10-Q
Revenue$99.22M$99.22M+121.7% vs Q3 2024 Net Income$7.41M$7.41MN/M vs Q3 2024 EPS Diluted$0.06$0.06N/M vs Q3 2024 Operating Income$8,526,000N/M Operating Cash Flow
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Arcutis Biotherapeutics, Inc. · CIK 1787306 · Engraved from SEC EDGAR
derived
Free Cash Flowderived-$1,754,000N/M Margins · derivedOperating margin8.6%+95.9 pt vs Q3 2024
Net margin7.5%+100.3 pt vs Q3 2024
ended Sep 30, 2025 · filed Oct 28, 2025 · 28 d after period end